drugset / Trial / NCT02521376
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.
Timeline
- Start
- 2015-11-16
- Primary completion
- 2017-10-25
- Completion
- 2017-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entospletinib | Small molecule | 100 mg | Oral |
Indications
No indication recorded.